.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Novartis
Express Scripts
McKesson
Julphar
Cerilliant
Harvard Business School
Medtronic
Citi
QuintilesIMS

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,004,968

« Back to Dashboard

Which drugs does patent 6,004,968 protect, and when does it expire?


Patent 6,004,968 protects EPIVIR and EPIVIR-HBV and is included in two NDAs. There have been zero Paragraph IV challenges on Epivir-HBV and Epivir

Protection for EPIVIR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-four patent family members in forty-three countries.

Summary for Patent: 6,004,968

Title: Pharmaceutical compositions containing lamivudine
Abstract:The present invention relates to pharmaceutical formulations containing (2R, cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2 -one (-)-2',3'-dideoxy,3'-thiacytidine, lamivudine, that are substantially free of ethanol and ethylenediamine-tetraacitic acid, and their use in medical therapy.
Inventor(s): Casey; Warren Michael (Knightdale, NC), Nguyen; Ngoc-Anh Thi (Durham, NC)
Assignee: Glaxo Wellcome Inc. (Research Triangle Park, NC)
Application Number:09/044,896
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Viiv HlthcareEPIVIRlamivudineSOLUTION;ORAL020596-001Nov 17, 1995AARXYesYes► Subscribe► Subscribe► SubscribeY
GlaxosmithklineEPIVIR-HBVlamivudineSOLUTION;ORAL021004-001Dec 8, 1998RXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,004,968

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9706295Mar 26, 1997

International Patent Family for Patent: 6,004,968

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China1255849► Subscribe
China1191061► Subscribe
Argentina011697► Subscribe
Austria295150► Subscribe
Australia7208498► Subscribe
Australia728461► Subscribe
Colombia4980849► Subscribe
Cyprus2569► Subscribe
Czech Republic298008► Subscribe
Czech Republic9903403► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Harvard Business School
Merck
Chinese Patent Office
Deloitte
Medtronic
Healthtrust
AstraZeneca
Federal Trade Commission
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot